Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bioo Scientific First to Address Small RNA-Seq Bias Concerns

Published: Wednesday, August 13, 2014
Last Updated: Wednesday, August 13, 2014
Bookmark and Share
Company launches NEXTflex™ Small RNA Sequencing Kit v2.

Bioo Scientific has launched the patent pending NEXTflex™ Small RNA Sequencing Kit v2, which utilizes randomized adapters to significantly reduce ligation bias from library preparation, resulting in the most accurate data available, as illustrated in a number of published papers.

The NEXTflex Small RNA Sequencing Kit v2 provides an easy, flexible, cost-effective solution for generating small RNA libraries for sequencing on Illumina sequencing platforms.

Traditional small RNA sequencing introduces bias at the ligation step, because no single adapter sequence is able to efficiently ligate to all small RNAs.

The NEXTflex Small RNA-Seq Library Prep Kit v2 overcomes this bias using randomized sequences at the ligation site. This randomized adapter strategy allows small RNAs of any sequence to “find” their respective optimal adapter, resulting in small RNA libraries with a dramatic reduction in bias.

The NEXTflex Small RNA Sequencing Kit v2 allows users to generate libraries directly from isolated small RNAs, microRNAs or total RNA. The protocol is designed to significantly reduce adapter dimer formation using an adapter depletion solution. Barcoded primers, added during PCR, are available separately, allowing up to 48 samples to be multiplexed.

According to Dr. Masoud Toloue, VP, Genomic Research, “One of Bioo Scientific’s primary focuses is the reduction of biases associated with next generation sequencing. The incorporation of randomized adapters is the latest innovative technology we’ve put into practice that allows for the most accurate sequencing-based measurement of small RNAs.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bioo Scientific Partners with the Icahn School of Medicine at Mount Sinai
Partnership to reduce ligation bias in next generation sequencing.
Saturday, February 14, 2015
Bioo Scientific Awarded Funding from NSF for the Biomolecular Detection of miRNA
The funding allows Bioo Scientific to develop a quantitative technology to measure miRNA expression in living cells or tumor tissue.
Wednesday, December 08, 2010
Bioo Scientific Awarded Funding from NSF for the Biomolecular Detection of miRNA
Bioo Scientific announced today that it has been awarded a grant of $150,000 from the National Science Foundation to support its research for the biomolecular detection of microRNA.
Wednesday, December 08, 2010
Bioo Scientific Chooses Eureka Genomics as its Next-Generation Sequencing Provider
Bioo Scientific chose Eureka Genomics based on their extensive sequencing experience, quick turnaround times and strong bioinformatics support.
Thursday, August 19, 2010
NSF Funds Research Partnership Between Bioo Scientific and Mirna Therapeutics
The funding will support tumor regression and pharmacokinetic studies on targeted delivery of microRNAs.
Thursday, July 22, 2010
Small RNA Barcoding for Sample Multiplexing
AIR Barcoded Adapters, designed to work with Illumina Next-Generation Sequencers, provide flexibility in high-throughput sequencing applications.
Monday, January 25, 2010
Bioo Scientific and Texas Tech Collaborate to Suppress the Progression of HIV Using Targeted RNAi
Dr Premlata Shankar, Professor and Co-Director, Center of Excellence of Infectious Disease Research at Texas Tech University, who has developed RNAi-based treatment methods for HIV infection, recently entered into a collaborative research agreement with Bioo Therapeutics, a division of Bioo Scientific, to leverage their T3™ technology to facilitate the targeted delivery of siRNA into T cells.
Tuesday, November 17, 2009
Bioo Scientific Launches a New Division, Bioo Therapeutics
Bioo Therapeutics will leverage Bioo Scientific’s proprietary drug delivery vehicles and antibody research expertise to develop therapeutic agents.
Thursday, November 12, 2009
Bioo Scientific Awarded SBIR Grant for Development of Targeted RNAi In Vivo Delivery Technology
A $500,000 Phase II grant will help to develop kits and reagents based on the patent-pending Targeted Transport Technology.
Wednesday, July 29, 2009
BIOO Scientific Corp. Receives Two Grants from US Agencies
Company receives NIH grant for improving antibody technology and launches a set of novel products for directed in vivo delivery of SiRNA.
Friday, January 04, 2008
Custom RNA Interference Service
BIOO Scientific is launching a service to perform in vivo RNAi testing to facilitate progress in the drug pipeline.
Thursday, April 12, 2007
Scientific News
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Enzyme Links Age-Related Inflammation, Cancer
Researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration.
Viral Gene Editing System Corrects Genetic Liver Disease
Penn study has implications for developing safe therapies for an array of rare diseases via new gene cut-and-paste methods.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Curing Disease by Repairing Faulty Genes
New delivery method boosts efficiency of CRISPR genome-editing system.
'Junk' DNA Plays Role in Preventing Breast Cancer
Supposed "junk" DNA, found in between genes, plays a role in suppressing cancer, according to new research by Universities of Bath and Cambridge.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!